The stock is in a short term consolidation stage. It bottomed at the end of September-17 and has been trending up in steps and has demonstrated resilience. In Q1-2018 the company is expected to announce results related to its CanaPsor014 which can propel the stock to the $2 - $3 range.
Psoriasis (Skin Disease)
• Preclinical “Dead Sea Study” showed up to 70%...
NASDAQ:ARLZ Short down wedge and closed below 200 MA. Any downside is limited to a nickel. Friday numbers may provide more fuel to the fire. Expecting consolidation until earnings November 7, at that point the stock will break the $3 mark.
AAOI We are in somewhat noisy period. It's quite obvious that somehow the true value of the company is not properly understood. As well as the complexity of what it does in production excellence and superiority.
Regardless, the fundamentals as they relate to sales, growth, MARGINS, financial strength are so strong that the company is ridiculously undervalued....
NASDAQ:ARLZ In addition to a clear structured technical formation the company's fundamentals point to an oversold and HIGH value play.
EPS (ttm) 1.10
Insider Own 0.80%
Shs Outstand 21.31M
Shs Float 20.45M
Short Float 51.47%
Market Cap 170.48M
Forward P/E 8.22 EPS
next Y 0.97
Insider Trans 19.69%
As previously published the cup action took us today to $2.98. The stock should begin a consolidation phase until earnings, or earlier as some announcement regarding debt restructuring/M&A is being expected for some time and could come any day now.
In mid-March the company announced restructuring of its sales force, reduction in operating expenses and changes in drug pricing. The stock plunged over 40% in 2 days and continued more than 6 months bear raid on the company. However, over that time the company is demonstrating consistent and impressive up trend in sales across the board of all its drug products....
NYSE:TWLO appears to have put a double bottom with stable 6 mo. support base between the high 20s to low 30s. The stock reversed last week and began an uptrend run. With decisively strong RSI, at highest level not seen since August 2016 it looks like $32-$35 can be achieved by the May 2 earnings release date. Since its HOT IPO runup in 6/2016 the company built a...
After 2.5 years ECA reversed its downtrend. At the end of January with deteriorating Natural Gas prices ECA price started going down and with oil prices slipping at the beginning of March the stock price continued the downtrend. While natural gas price started trending up the stock did not reflect that and continued to follow Oil Prices. It appears that when NG...